Cargando…
The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment
BACKGROUND: Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a deeper understanding of treatment impact beyond clinical endpoints. Developing and administering PROMs for rare diseases poses un...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357707/ https://www.ncbi.nlm.nih.gov/pubmed/33462774 http://dx.doi.org/10.1007/s40271-020-00493-w |
_version_ | 1783737186963685376 |
---|---|
author | Whittal, Amanda Meregaglia, Michela Nicod, Elena |
author_facet | Whittal, Amanda Meregaglia, Michela Nicod, Elena |
author_sort | Whittal, Amanda |
collection | PubMed |
description | BACKGROUND: Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a deeper understanding of treatment impact beyond clinical endpoints. Developing and administering PROMs for rare diseases poses unique challenges because of small patient populations, disease heterogeneity, lack of natural history knowledge, and short-term studies. OBJECTIVE: This research aims to identify key factors to consider when using different types of PROMs in HTA for rare disease treatments (RDTs). METHODS: A scoping review of scientific and grey literature was conducted, with no date or publication type restrictions. Information on the advantages of and the challenges and potential solutions when using different types of PROMs for RDTs, including psychometric properties, was extracted and synthesized. RESULTS: Of 79 records from PubMed, 32 were included, plus 12 records from the grey literature. PROMs for rare diseases face potential data collection and psychometric challenges resulting from small patient populations and disease heterogeneity. Generic PROMs are comparable across diseases but not sensitive to disease specificities. Disease-specific instruments are sensitive but do not exist for many rare diseases and rarely provide the utility values required by some HTA bodies. Creating new PROMs is time and resource intensive. Potential solutions include pooling data (multi-site/international data collection), using computer-assisted technology, or using generic and disease-specific PROMs in a complementary way. CONCLUSIONS: PROMs are relevant in HTA for RDTs but pose a number of difficulties. A deeper understanding of the potential advantages of and the challenges and potential solutions for each can help manage these difficulties. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40271-020-00493-w. |
format | Online Article Text |
id | pubmed-8357707 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-83577072021-08-30 The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment Whittal, Amanda Meregaglia, Michela Nicod, Elena Patient Review Article BACKGROUND: Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a deeper understanding of treatment impact beyond clinical endpoints. Developing and administering PROMs for rare diseases poses unique challenges because of small patient populations, disease heterogeneity, lack of natural history knowledge, and short-term studies. OBJECTIVE: This research aims to identify key factors to consider when using different types of PROMs in HTA for rare disease treatments (RDTs). METHODS: A scoping review of scientific and grey literature was conducted, with no date or publication type restrictions. Information on the advantages of and the challenges and potential solutions when using different types of PROMs for RDTs, including psychometric properties, was extracted and synthesized. RESULTS: Of 79 records from PubMed, 32 were included, plus 12 records from the grey literature. PROMs for rare diseases face potential data collection and psychometric challenges resulting from small patient populations and disease heterogeneity. Generic PROMs are comparable across diseases but not sensitive to disease specificities. Disease-specific instruments are sensitive but do not exist for many rare diseases and rarely provide the utility values required by some HTA bodies. Creating new PROMs is time and resource intensive. Potential solutions include pooling data (multi-site/international data collection), using computer-assisted technology, or using generic and disease-specific PROMs in a complementary way. CONCLUSIONS: PROMs are relevant in HTA for RDTs but pose a number of difficulties. A deeper understanding of the potential advantages of and the challenges and potential solutions for each can help manage these difficulties. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40271-020-00493-w. Springer International Publishing 2021-01-19 2021 /pmc/articles/PMC8357707/ /pubmed/33462774 http://dx.doi.org/10.1007/s40271-020-00493-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Article Whittal, Amanda Meregaglia, Michela Nicod, Elena The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment |
title | The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment |
title_full | The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment |
title_fullStr | The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment |
title_full_unstemmed | The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment |
title_short | The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment |
title_sort | use of patient-reported outcome measures in rare diseases and implications for health technology assessment |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357707/ https://www.ncbi.nlm.nih.gov/pubmed/33462774 http://dx.doi.org/10.1007/s40271-020-00493-w |
work_keys_str_mv | AT whittalamanda theuseofpatientreportedoutcomemeasuresinrarediseasesandimplicationsforhealthtechnologyassessment AT meregagliamichela theuseofpatientreportedoutcomemeasuresinrarediseasesandimplicationsforhealthtechnologyassessment AT nicodelena theuseofpatientreportedoutcomemeasuresinrarediseasesandimplicationsforhealthtechnologyassessment AT whittalamanda useofpatientreportedoutcomemeasuresinrarediseasesandimplicationsforhealthtechnologyassessment AT meregagliamichela useofpatientreportedoutcomemeasuresinrarediseasesandimplicationsforhealthtechnologyassessment AT nicodelena useofpatientreportedoutcomemeasuresinrarediseasesandimplicationsforhealthtechnologyassessment |